UNITED STATES ANTIMONY CORP (UAMY): Nasdaq/NYSE listing notice — US Antimony receives NYSE American delisting notice for late 10-K filing

UNITED STATES ANTIMONY CORP

NYSE American notified UAMY on April 18, 2023 of non-compliance with timely filing criteria under Section 1007.
Company has until October 17, 2023 to file the delinquent 2022 Form 10-K; a six-month extension may be available.
Delayed filing due to independent auditors needing more time; 2022 10-K remains unfiled.
NYSE American can truncate cure period and commence delisting proceedings at any time.
No immediate impact on UAMY stock listing or trading on NYSE American.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

UNITED STATES ANTIMONY CORP received a nyse_american deficiency notice notice regarding late filing (rules 1007).

Exchange: nyse american
Notice: deficiency notice
Deficiency: late filing
Rules: 1007

Exact text from the filing

April 18, 2023, United States Antimony Corporation (NYSE: UAMY), a Montana Corporation (the “Company”) received a notification letter (the “NYSE Notice) from the New York Stock Exchange (the “NYSE”) indicating that, as a result of the Company’s delay in filing its Annual Report on its Form 10-K for the period ended December 31, 2022 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”) the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing criteria established in Section 1007 of the NYSE American Company Guide. The n

View on SEC.gov

Browse all listing & compliance notices →

UNITED STATES ANTIMONY CORP filing history →

Source: SEC EDGAR

accession 0001654954-23-005074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.